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ABSTRACT. Caseous lymphadenitis is a chronic suppurative bacterial disease caused by Corynebacterium pseudotuberculosis, 
and it has a high prevalence among small ruminants. Different vaccine preparations have been employed to control this disease. The 
adjuvant used in the formulation is a critical factor for the improvement of vaccine efficacy. No commercial vaccines are available in 
Argentina. The aims of the present work were to compare the specific antibody response against a C. pseudotuberculosis whole cell 
vaccine formulated with a classical and an immunoestimulant adjuvant in pregnant goats, and to assess the transfer of vaccine-specific 
antibodies from the goat to the offspring through colostrum. Twenty three pregnant goats were vaccinated. The animals were randomly 
allocated to three groups: control, aluminum hydroxide Al(OH)3 adjuvant and a new cage-like particle adjuvant (ISPA). Antibodies 
(IgG) against this antigen were measured by ELISA. A robust humoral immune response was detected in vaccinated animals, with 
production of specific IgG. No significant differences were found between the vaccines formulated with different adjuvants. High 
levels of specific antibodies were detected in colostrum samples from both immunised groups, which were passively transferred from 
goats to offprings. No adverse local reactions in the vaccines injection sites were detected.
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INTRODUCTION
Caseous lymphadenitis, also called pseudotubercu-
losis, is a chronic suppurative bacterial disease caused 
by Corynebacterium pseudotuberculosis that presents a 
worldwide distribution and has a high prevalence among 
small ruminants, also affecting cows, horses and other 
domestic animals (Belchior et al 2006). In addition, it 
has been currently recognised as an emerging zoonotic 
disease (Palmero et al 2013). 
There is scarce information about the prevalence of this
disease in goat herds in Argentina, which appears to vary 
according to the geographical area and type of production 
system. In the North West of the country, particularly in 
the arid ravine of Jujuy and Salta, a 60% prevalence of 
pseudotuberculosis was reported recently (Suárez et al 
2016), whereas in the Chaco Salteño area the prevalence 
was only 15.6% (Suárez et al 2015). 
Pseudotuberculosis is characterised by the formation 
of encapsulated abscesses containing thick, caseous pus, 
most frequently within peripheral lymph nodes, but also 
within internal lymph nodes and organs (Fontaine et al 
2006). Economic losses are mainly due to the progressive 
deterioration of the general condition of the animal, which 
results in decreased production of wool, meat, milk, as 
well as reproductive disorders and confiscation of viscera
at the slaughterhouse (Belchior et al 2006). 
C. pseudotuberculosis can become endemic in a herd 
and disease eradication is problematic due to poor response 
to antibiotic therapy, organism ability to persist in the 
environment and difficulties in detecting subclinically 
infected animals (Al-gaabary et al 2009). The situation 
is aggravated by the absence of commercial vaccines 
available in Argentina (Palmero et al 2013).
There are numerous reports on vaccination against C. 
pseudotuberculosis in ovine species, with few studies in 
goats (Baird et al 2007). Different antigen preparations 
have been employed, such as formalin-killed bacterins, 
bacterial cell wall preparations, phospholipase D toxoid 
and the use of immunostimulants including oligodeoxynu-
cleotide containing unmethylated CpG dinucleotides with 
little success (Brogden et al 1996, Brogden et al 1984, 
Eggleton et al 1991, Cameron et al 1972, Moura-Costa 
et al 2008, Brown et al 1986) . 
The adjuvant used in the formulation is considered a 
critical factor for the improvement of vaccine efficacy. The 
most frequently employed adjuvants in veterinary vaccines 
have been Freund’s incomplete adjuvant (Moura-Costa et 
al 2008) and Al(OH)3 (Fontaine et al 2006). New immu-
nostimulant complexes (ISCOM) have been developed 
(Morein et al 1984, Sjölander et al 1998). These com-
pounds induce strong cellular or humoral antigen-specific 
immune responses to a wide range of antigens (Sun et al 
2009), being both antigens and adjuvant formulated in 
one and the same nanoparticle (Morein et al 2004). These 
nanoparticles are composed of saponins, cholesterol and 
phospholipids that are kept together through hydrophobic 
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interactions (Morein et al 2004). The capabilities of this 
type of adjuvant are not restricted to particulate antigens, 
a recent study reported the use of ISCOMATRIXTM as 
an adjuvant for a Staphylococcus aureus whole cell vac-
cine that was evaluated in cattle with promising results 
(Camussone et al 2013). In addition, a new cage-like 
particle adjuvant (ISPA), structurally similar to ISCOM, 
was recently developed and evaluated in a murine model 
using a Trypanosoma cruzi recombinant protein antigen 
(Bertona et al 2017). However, the potential synergic 
effect of this adjuvant in the use of whole cell vaccines 
has not been evaluated.
In goats, the newborn lacks specific protection against 
the pathogenic challenges of the environment, since the 
syndesmocorial type of placenta does not allow the passage
of antibodies. Therefore, the immunoglobulins synthesized 
and derived from the goat should be transferred through 
colostrum (Cooper et al 2014, Fernández et al 2006, 
Iepema et al 2008, Rudovsky et al 2008). Pregnant females 
should be vaccinated at approximately 4 weeks before the 
probable date of birth for an adequate transfer of passive 
immunity through colostrum to control specific infectious 
diseases.
The aim of the present work was to evaluate the spe-
cific antibody response against a C. pseudotuberculosis 
whole-cell vaccine formulated with Al(OH)3 and ISPA 
adjuvant in pregnant goats, and to assess the transfer of 
vaccine-specific antibodies from goat to offspring through 
colostrum. 
MATERIAL AND METHODS
PREPARATION FORMALIN-KILLED C. pseudotuberculosis 
VACCINE (FKC)
The vaccine was formulated using the method described 
by Fontaine et al (2006) with slight modifications. C. 
pseudotuberculosis (UTK 224), previously characterised 
by phenotypic and molecular methodology (Auad et al 
2017), was briefly cultured on blood agar (BA) plates, and 
bacterial colonies were collected using sterile, cotton-tipped 
swabs moistened with sterile PBS. Bacterial cells were 
quantified by standard methodology and approximately 
109 CFU were suspended in 20 ml of PBS and formalin 
was added to a final concentration of 0.2% (v/v). Cells 
were incubated overnight at 4 ºC. Aliquots of 100 µl of the 
bacterial suspension were plated onto BA plates, incubated 
at 37 ºC and monitored daily for 5 days to confirm bacterial 
killing. Bacterial cells were pelleted by centrifugation at 
3,000 g and resuspended in PBS. The vaccines were for-
mulated using a different adjuvant. Aluminum hydroxide 
(Alhydrogel™) was added to bacterial suspension to 15% 
(v/v) final concentration and incubated during 1 h at 100 
rpm. Immune stimulating particles (ISPA) were added to 
bacterial suspension at 2 mg/ml final concentration and 
mixed by inversion (Bertona et al 2017). 
ANIMALS AND TREATMENTS
Twenty three pregnant goats in the last trimester of 
gestation and thirty goat kids obtained by crossbreeding 
Criollo x Anglo Nubian and belonging to a goat farm 
located in Córdoba province, Argentina, were randomly 
allocated to three groups: G1 (control group): 9 goats 
vaccinated with saline solution and 13 goat kids; G2: 8 
female goats vaccinated with FKC of C. pseudotubercu-
losis in Al(OH)3 adjuvant and 8 goat kids; and G3: 6 goats 
vaccinated with FKC of C. pseudotuberculosis in ISPA 
adjuvant and 9 goat kids.
Goats were immunised subcutaneously behind the 
front leg with 1 ml of vaccine at approximately 110 (first 
dose) and 131 (second dose) days of gestation according 
to the expected day of parturition. Goats were bled by 
puncture of the jugular vein before immunisation (T0), 
21 days after first immunisation (T1), and at the time of 
parturition (T2). Newborns were bled 48 hours after birth. 
Blood was allowed to clot and sera were collected and 
centrifuged at 1000 x g for 10 minutes. 
After parturition, colostrum samples were collected 
and centrifuged at 13,800 x g for 10 minutes, supernatants 
were collected and stored at -80 °C until processing.
All the procedures were carried out according to the 
Guide for the Care and Use of Agricultural Animals in 
Agricultural Research and Teaching1. 
SEROLOGY
Antibodies (total IgG) against C. pseudotuberculosis 
were measured by ELISA. Flat-bottomed 96-well mi-
crotitre plates were coated with a suspension of bacterin 
(1x107 CFU/well) in PBS (pH 7.2) as previously described 
(Camussone et al 2013). The coated plates were first in-
cubated with 5% low-fat cow milk in PBS and then with 
goat´s sera or colostrum diluted in PBS or with PBS only 
as blank control. Between each step, plates were washed 
three times with 0.05% Tween 20 in PBS. After washing, 
peroxidase-conjugated rabbit anti-goat IgG (Pierce®) was 
added. All incubations were 1 h at 37 °C. Lastly, enzyme 
substrate (H2O2/tetrametylbenzidine) was added and the 
reaction was stopped by the addition of 0.25 m-H2SO4. 
The absorbance was read at 450 nm (Infinite® F50, Tecan, 
Austria) as previously described (Camussone et al 2013). 
Antibody levels were expressed as optical density (OD). 
Samples were assayed in duplicate. Working dilutions of 
goats sera, goat kids sera and colostra were 1/5000, 1/2500 
and 1/10000, respectively.
1 FASS, Federation of Animal Sciences Societies. 2010. Guide for 
the care and use of agricultural animals in research and teaching. 
3rd ed. FASS Champaign, Ilinois, USA; http://www.fass.org/docs/
agguide3rd/Ag_Guide_3rd_ed.pdf 
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STATISTICAL ANALYSIS
In order to test the differences caused by immunisation, 
one way repeated measures Anova was performed using 
Rank transformation because the residuals are not normal 
and homoscedastic (Sokal and Rohlf 1995). One way Anova 
on colostrum and kid sera values was performed. In all the 
cases, Student Newman Keuls post hoc was performed, 
significance was 5% and the software used was R version 
3.3.2 (R Core Team 2016). Mean and standard deviations 
were reported.
RESULTS AND DISCUSSION
ANTIBODY RESPONSE IN SERA
No differences in antibodies levels against C. pseudo-
tuberculosis were detected at T0 between animals in 
Al(OH)3, ISPA or control groups. At 21 days after the first 
immunisation (T1), the group of animals vaccinated with 
bacterin formulated with Al(OH)3 (G2) showed significant 
differences with respect to the control group (G1), while no 
differences were observed between the group vaccinated 
with bacterin formulated with ISPA (G3) and the control 
group (G1). At the time of birth (T2) both vaccinated 
groups showed significant differences with respect to the 
control group (table 1). 
Anti IgG specific response between goats from the 
same group was also compared. No differences in IgG 
levels were observed within the control group at any 
sampling time (G1). In goats vaccinated with bacterin 
formulated with Al(OH)3 (G2), differences in serum IgG 
levels between T0 and T1 were observed. However, after 
administration of the second vaccine dose (T2), IgG levels 
did not increase significantly. In G3 (animals vaccinated 
with ISPA as adjuvant), significant differences were found 
between T0 and T1 and between T1 and T2 (figure 1). 
The antibody response presented significant changes in 
time (F=58.641; P<0.001) and this changes were related 
to the effect of immunisation (F=8,698; P=0.002) and to 
the interaction between them (F=41,497; P<0.001).
After the administration of two doses of vaccine, both 
immunised groups showed an increase in IgG specific for C. 
pseudotuberculosis. In previous studies carried out in two 
groups of goats, one inoculated with secreted C. pseudo-
tuberculosis antigen associated with Freund’s incomplete 
adjuvant and the other group with oligodeoxynucleotide 
containing unmethylated CpG dinucleotides (CpG ODN), 
a significant increase in humoral immune response after 
vaccination was observed (Moura-Costa et al 2008). 
However, differences between C. pseudotuberculosis 
antigens and adjuvants used for vaccines formulations, do 
not allow for direct comparisons with the present study.
There is little experience in the usage of immune stimu-
lating complexes in the formulation of whole-cell vaccines. 
In a previous work, immunisation of pregnant heifers with 
a S. aureus bacterin formulated with ISCOMATRIX™ in-
duced specific total IgG responses in sera and milk; higher
than those obtained with the same immunogen formulated 
with Al(OH)3 (Camussone et al 2013). In addition, it 
was observed that ISCOMATRIXTM adjuvant associated 
with viral antigens generated enhanced and accelerated 
immune responses in mice and Guinea pigs (reviewed by 
Maraskovsky et al 2009). These observations differ from 
results obtained in the present study, since regardless of 
the adjuvant used, the total IgG response did not differed 
significantly between vaccinated groups, both in serum 
and colostrum. However, direct comparisons with previous 
studies are difficult due to differences in the antigens (bac-
terin vs viral antigens), animal species and adjuvants used.
ANTIBODIES IN COLOSTRUM
Immunised goats yielded significantly higher levels 
of anti- C. pseudotuberculosis specific IgG antibodies in 
colostrum than goats from the control group. No differences 
were observed in IgG levels between animals in Al(OH)3 
or ISPA groups (table 2).
PASSIVE TRANSFER OF ANTI-C. pseudotuberculosis SPECIFIC 
ANTIBODIES 
At 48 hours post-birth, newborns from immunized 
goats evidenced significantly higher levels of IgG anti-C. 
pseudotuberculosis in sera than those from control mothers; 
being IgG levels in newborns from Al(OH)3 group similar 
Table 1. Antibody levels in pregnant goats immunised with a C. pseudotuberculosis vaccine formulated with different adjuvants at dif-
ferent times of study (T0: before immunisation; T1: 21 days after first immunisation; T2: time of parturition)*. OD means and standard 
deviation (SE) of IgG specific in goat’s serum. Different letters imply significant differences.
T0 T1 T2
Overall
Mean SE Mean SE Mean SE
CONTROL (G1) A 0.1272 0.0232 A 0.1184 0.0235 A 0.1110 0.0179 A
Al(OH)3 adjuvant (G2) A 0.1213 0.0138 B 0.2310 0.1942 B 0.3710 0.2617 B
ISPA adjuvant (G3) A 0.1119 0.0123 AB 0.2134 0.0669 B 0.4148 0.1627 B
*Differences between groups at different times were analysed.
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to those from ISPA group (table 2). A higher concentration 
of specific colostral antibodies was observed in vaccinated 
animals, regardless of the vaccine used. In the present study, 
both evaluated formulations achieved the passive transfer of 
immunity to goat kids. Although no direct comparisons can 
be made due to the different nature of vaccines employed, 
the manufacturer of a commercial C. pseudotuberculosis 
vaccine for goats (Glanvac® 3 for goats - Zoetis - Australia), 
recommends to vaccinate pregnant naïve animals with 1 
ml dose of vaccine at the time of mating and a booster 
vaccination 4 weeks before the expected time of kidding 
to allow protection of the kids the first 6 to 8 weeks of life 
due to the passage of antibodies through the colostrum. 
Regarding the vaccine evaluated in the present experiment, 
further studies will be needed to determine the antibodies 
half-life to design a vaccination schedule for the kids to 
allow for extended protection.
In conclusion, a strong specific total IgG response was 
observed for the vaccine formulated with both adjuvants 
without finding differences between the formulations 
used. However, this response was earlier in those goats 
that received the vaccine formulated with Al(OH)3 as an 
adjuvant. In addition, high levels of specific antibodies 
were transferred to the goat kids through colostrum from 
both immunised groups and no adverse reactions were 
observed in the vaccines inoculation sites.
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Table 2. Antibody levels in colostrum of goats and sera of goat kids following immunisation of pregnant goats with a C. pseudotuber-
culosis vaccine formulated with different adjuvants. OD means and standard deviation (SE) of IgG specific in colostrum and goat kid´s 
serum. Different letters imply significant differences.
Colostrum Goat kids (48 hours)
Mean SE Mean SE
CONTROL (G1) A 0.1318 0.0306 A 0.1179 0.022
Al(OH)3 adjuvant (G2) B 0.8059 0.4897 B 0.5409 0.1962
ISPA adjuvant (G3) B 0.7593 0.3782 B 0.7117 0.2179
Figure 1. Serum antibody levels within each group of pregnant goats immunised with a C. pseudotuberculosis vaccine formulated 
with different adjuvants over time (T0: before immunization; T1: 21 days after first immunisation; T2: time of parturition)*. Specific 
IgG is expressed in OD. References: G1: control; G2: FKC in Al(OH)3 adjuvant; G3: FKC in ISPA adjuvant. Different letters imply 
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